Targeting Non-Liver Tissues
Gene therapy is a new reality. Drugs made out of DNA or RNA have a lot of potential. They can specifically turn any gene on or off, which allows them to treat disease at its genetic roots.
However, without cost-effective, safe, and efficient drug delivery to the diseased tissue, these gene therapies will not reach patients. Nanoparticles and other drug delivery systems are emerging as a next-generation technology to deliver gene therapies into target cells. But so far, drug delivery has been limited to the liver.
Utilizing a proprietary high throughput screening platform, GuideRx has developed a new way to rapidly and efficiently develop nanoparticles to deliver genetic drugs beyond the liver. We can now run up to 20,000 drug delivery experiments simultaneously, all in vivo.
Once we find drug delivery vehicles that safely target new tissues, we develop genetic drugs internally or team up with strategic partners.
Rapid discovery of nanoparticles that target new tissues
We can deliver any gene therapyWe have developed a suite of increasingly sensitive methods to track how thousands of drug delivery systems work in vivo. By radically streamlining the pre-clinical ‘pipeline’ used to develop safe nanoparticles, we can rapidly select cutting-edge nanoparticles that deliver genetic drugs to new tissues.
Our Approach: Rapidly Testing Thousands of Nanoparticles Directly In Vivo
High on-target delivery; more efficacy Low off-target delivery; fewer side effects
Increasing the rate of discovery 15,000 fold
Tom Saylor, CEO
Tom has served as CEO of several emerging biotech companies both in Europe and Asia. Most recently he was as CEO of Arecor Limited, a British company focused upon enabling the next generation of therapeutic proteins and vaccines through advanced formulation technologies. Previously, he was CEO of Sirus Limited, a drug targeting and delivery company based in Cambridge, England. Read more >
James Dahlman, Co-Founder
James is a molecular engineer whose work lies at the interface of chemistry, nanotechnology, genomics, and gene editing. He is an Assistant Professor in the Georgia Tech BME Department, where his lab focuses on targeted drug delivery, in vivo gene editing, Cas9 therapies, siRNA therapies, and developing new technologies to improve biomaterial design. Read more >
Cory Sago, Founding Scientist
Cory is a Ph.D. candidate in precision therapies in the DahlmanLab at Georgia Tech, where he is a lead developer of DNA barcoding technologies. Previously, he was an undergraduate researcher for Professor Richard Gross at Rensselaer Polytechnic Institute working on multiple topics in the fields of drug delivery, tissue engineering and bio-based materials. Read more >